FREXALT: Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Jul 5, 2026 - P3 | N=1655 | Sponsor: Sanofi | N=92 ➔ 1655
Enrollment change • CNS Disorders • Multiple Sclerosis • NEFL • Plasma NfL
|